RESOLUTE China RCT
A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 400 participants.
Also called NCT01334268
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 400 participants
- Sponsor
- Registry
-
NCT01334268
-
- Main results
- Zotarolimus- and paclitaxel-eluting stents in an all-comer population in China: the RESOLUTE China randomized controlled trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT01334268. Randomized; single masking; primary purpose treatment. Start 2011-09 (actual); primary completion 2012-11 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- RESOLUTE China RCT
- Acronym
- R-China RCT
- Condition
- Ischemic Heart Disease
- Condition
- Stenotic Coronary Lesion
- Condition
- Cardiovascular Diseases
- Condition
- Arteriosclerosis
- Condition
- Coronary Artery Disease
- Intervention (Device)
- Taxus Liberte Paclitaxel-Eluting Coronary Stent System
- Intervention (Device)
- Resolute Zotarolimus-Eluting Coronary Stent System
- Lead sponsor
- Medtronic Vascular
Record details
- Record id
cardio:ct-nct01334268- Content hash
8d5f989cab786cc30055c35adf6f5f0b0781ad5cc5dd8dbdd55c9e118898831b